The Archway study (NCT03677934) was a phase 3, randomized, active treatment–controlled trial for the treatment of nAMD, conducted at 77 study locations in the United States. We caught up with Prof. Usha Chakravarthy (Queen’s University of Belfast, Belfast, Northern Ireland) to discuss the causes of persistent fluid in neovascular age-related macular degeneration and the impact on visual and anatomical outcomes
The abstract ‘Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the Port Delivery System With Ranibizumab (PDS)’ was presented at EURETINA 2022, 1–4 September 2022
- What are the causes of the development of persistent fluid in neovascular age-related macular degeneration? (00:17)
- What is the impact of fluid on visual and anatomical outcomes in neovascular age-related macular degeneration? (01:00)
- What are the key take home messages of your presentation? (03:07)
Disclosure: Usha Chakravarthy has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of EURETINA 2022.
